TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:46:08+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] SC 13G: 1. Names of Reporting Persons. Popeset Management, I.R.S.

[1. Names of Reporting Persons. Popeset Management, I.R.S. Identification Nos. ofove persons 62-1871308 2. Check the Appropriate Box if a Member of a (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Tennessee Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 2,224,831* 6. Shared Voting Power]

By | 2016-02-07T21:44:41+00:00 February 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:46:56+00:00 February 14th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G: (Original Filing)

[USIP O C 13G Page 13 of 14 Joint Filing Agreement February 14, 2013 This Agreement may be executed in multiple counterparts, each of which shall constitute an original, one and the same instrument. Commonwealth Bank of Australia Colonial Holding Company Limited Commonwealth Insurance Holdings Limited Colonial First State Group Limited First State Investment Management (UK) Limited] [USIP O C 13G Page 14 of 14 Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) EX-99.2] [1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Commonwealth Bank of Australia 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ x (a) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Australian Capital Territory, Commonwealth of Australia NUMBER OF SHARES BENEFICIALLY]

By | 2016-04-02T17:15:17+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: (Original Filing)

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-27T18:47:54+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G: USIP O C 13G Page 13 of 14

[USIP O C 13G Page 13 of 14 Joint Filing Agreement February 14, 2013 This Agreement may be executed in multiple counterparts, each of which shall constitute an original, one and the same instrument. Commonwealth Bank of Australia Colonial Holding Company Limited Commonwealth Insurance Holdings Limited Colonial First State Group Limited First State Investment Management (UK) Limited] [USIP O C 13G Page 14 of 14 Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) EX-99.2] [1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Commonwealth Bank of Australia 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP ¨ x (a) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Australian Capital Territory, Commonwealth of Australia NUMBER OF SHARES BENEFICIALLY]

By | 2016-04-02T17:16:15+00:00 February 14th, 2013|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] SC 13G/A: (Name of Issuer) Common Stock (Title of Class

[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]

By | 2016-03-24T00:48:10+00:00 February 14th, 2013|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: for a reporting persons initial filing on this

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-27T18:49:46+00:00 February 14th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G/A: (Original Filing)

[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 80,157,688 Item 6: 0 Item 7: 83,982,488 Item 8: 0 Item 9: 83,982,488 Item 11: 14.622% Item 12: HC Cusip #G98079109 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 83,982,488 Item 8: 0 Item 9: 83,982,488 Item 11: 14.622%]

By | 2016-04-02T17:17:57+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G/A: Item 1: Reporting Person – FMR LLC Item

[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 80,157,688 Item 6: 0 Item 7: 83,982,488 Item 8: 0 Item 9: 83,982,488 Item 11: 14.622% Item 12: HC Cusip #G98079109 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 83,982,488 Item 8: 0 Item 9: 83,982,488 Item 11: 14.622%]

By | 2016-04-02T17:18:57+00:00 February 14th, 2013|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments
Skip to toolbar